三醇的化学和治疗方面:深入了解结构-活性关系
Shikha Sharma1, Nitin Mittal1, Bimal Krishna Banik2
1Department of Pharmaceutical Science, Lords University, Alwar 301028, India.
Current pharmaceutical design
|November 2, 2023
概括
三醇化合物是重要的含的异环,具有广泛的药理潜力. 这篇评论强调了它们多样化的抗菌,抗病毒和抗炎性质,强调了它们在药物化学中的重要性.
科学领域:
- 药用化学 医学化学
- 有机化学 有机化学
- 药理学 药理学是指药理学的学科.
背景情况:
- 三醇环是天然产品和药品中发现的关键异环结构.
- 含的异环在药物化学中因其生物潜力而越来越突出.
- 三醇作为其他异环环的生物异构剂,如氧化醇,提供修饰性质.
研究的目的:
- 探索三醇部分的广泛药理特性.
- 审查基于三醇的化合物的多目标活性.
- 突出三醇衍生物在各种应用中的治疗潜力.
主要方法:
- 关于科学文章和研究论文的综合文献评论.
- 对聚焦于三醇化合物的合成和生物评估的研究的分析.
- 汇编了有关三醇支架所产生的各种药理学活动的数据.
主要成果:
- 醇衍生物表现出广泛的药理活性,包括抗菌,抗病毒和抗炎作用.
- 鉴定出具有重要的抗,止痛,抗,抗结核和抗疟疾性质.
- 观察到有强大的抗氧化活性和与三醇相关的其他治疗益处的证据.
结论:
- 基于triazole的化合物具有显著和多样化的药理潜力.
- 三醇支架是开发新型治疗剂的有价值框架.
- 对于各种药物应用,对三醇衍生物的进一步研究是有必要的.
相关概念视频
Structure-Activity Relationships and Drug Design
734
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
734
Adrenergic Agonists: Chemistry and Structure-Activity Relationship
3.1K
Adrenergic agonists' structure-activity relationship (SAR) determines their selectivity and efficacy. These agonists comprise a phenylethylamine moiety with an aromatic ring and an ethylamine side chain.
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of...
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of...
3.1K
Cholinergic Antagonists: Chemistry and Structure-Activity Relationship
2.3K
Cholinergic antagonists bind to cholinergic receptors and limit the effects of acetylcholine and other cholinergic agonists. Based on the specific cholinergic receptor affinity, these antagonists are classified as muscarinic or nicotinic. Anticholinergics interrupt parasympathetic innervations while sympathetic innervations remain uninterrupted. Muscarinic antagonists are also called 'muscarinic antagonists', 'antimuscarinics', or 'parasympatholytics'. Nicotinic...
2.3K
Aryldiazonium Salts to Azo Dyes: Diazo Coupling
3.0K
The reaction of weakly electrophilic aryldiazonium (also called arenediazonium) salts with highly activated aromatic compounds leads to the formation of products with an —N=N— link, called an azo linkage. This reaction, presented in Figure 1, is known as diazo coupling and occurs without the loss of the nitrogen atoms of the aryldiazonium salt. Highly activated aromatic compounds such as phenols or arylamines favor the diazo coupling reaction. The coupling generally occurs at the...
3.0K
Direct-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship
1.1K
Cholinergic agonists or cholinomimetics mimic the action of acetylcholine to stimulate the parasympathetic nervous system. They are categorized into direct-acting and indirect-acting agents. The direct-acting cholinergic drugs induce the parasympathetic response by directly binding to the muscarinic or nicotine receptors. In comparison, the indirect-acting cholinergic drugs prevent acetylcholine hydrolysis, indirectly contributing to the extended parasympathetic response.
The direct-acting...
The direct-acting...
1.1K
Drug Administration and Therapy Phases: Overview
483
Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
483


